Dr. Louis Bessette graduated from medical school and completed his residency in Internal Medicine and Rheumatology at Laval University. He trained as a fellow in clinical research at the Multipurpose Arthritis Center, Brigham and Women’s Hospital in Boston and received a master’s degree in epidemiology from the Harvard School of Public Health.
He is a clinical researcher at the Centre de recherche du CHU de Québec-Laval University, assistant professor at Laval University’s School of Medicine. Since 2014, he has been Chief of the Rheumatology Department at the CHU de Québec-Laval University. His main research interests are rheumatoid arthritis and osteoporosis, as well as the quality of life aspects and pharmacoeconomic studies related to these diseases.
Dr. Bessette is the principal investigator of the CATCH study in Quebec City (Canadian Early Arthritis Cohort Study). CATCH is a Canadian multicentre research program that aims at improving the quality of care for people with early inflammatory arthritis. Over 2,000 people are participating in our investigator-initiated research program across Canada (100 subjects in Quebec City). This is the only Canada-wide early arthritis cohort that follows people with new onset inflammatory or rheumatoid arthritis over time to examine the course of their disease and their response to the treatments provided by their healthcare team.
He is co-investigator of the Group for Early Arthritis Research (GEAR). GEAR is a multidisciplinary team of the CHU de Québec-Laval University composed of clinicians and clinical researchers in the field of rheumatology. A model for an early arthritis clinic was put in place in 2014 to give better and earlier access to patients who suffer from rheumatic conditions. Other objectives are to collect clinical data and bio specimens on patients with early arthritis to better understand disease progression and its complications. Collecting these data and bio specimens will provide information on the population in the CHU de Québec-Laval University catchment area, and allow to elaborate strategies to improve patient care and prevent comorbid conditions in patients with early arthritis.
Dr. Bessette is co-director for the CaMOS Quebec City Centre, a large Canadian epidemiologic study in osteoporosis. He is also co-investigator of the Recognizing Osteoporosis and its Consequences in Quebec (ROCQ) Programme, a patient health-management programme aimed at evaluating the diagnostic and treatment care gaps for osteoporosis following a fragility fracture in women aged 50 years and over.
2705, boulevard Laurier
T0-93
Québec, Québec
Canada G1V 4G2
Latest news
Data not available
Characteristics of patients with difficult-to-treat rheumatoid arthritis: a descriptive retrospective cohort study
Journal ArticleAdv Rheumatol, 64 (1), 2024.
Barriers to, Facilitators of, and Interventions to Support Treat-to-Target Implementation in Rheumatoid Arthritis: A Systematic Review
Journal ArticleArthritis Care Res (Hoboken), 2024.
Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study
Journal ArticleRheumatol Ther, 11 (2), 2024.
Real-World Effectiveness of Upadacitinib for Treatment of Rheumatoid Arthritis in Canadian Patients: Interim Results from the Prospective Observational CLOSE-UP Study
Journal ArticleRheumatol Ther, 11 (3), 2024.
Having More Tender Than Swollen Joints is Associated With Worse Function and Work Impairment in Patients With Early Rheumatoid Arthritis
Journal ArticleACR Open Rheumatol, 6 (6), 2024.
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE
Journal ArticleRheumatol Ther, 11 (3), 2024.
Having More Tender Than Swollen Joints Is Associated With Worse Patient-Reported Outcomes in Patients With Early RA
Journal ArticleJ Clin Rheumatol, 30 (5), 2024.
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study
Journal ArticleRMD Open, 10 (2), 2024.
Which advanced treatment should be used following the failure of a first-line anti-TNF in patients with rheumatoid arthritis? 15 years of evidence from the Quebec registry RHUMADATA
Journal ArticleRheumatology (Oxford), 2024.
Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Living Treatment Recommendations for the Management of Axial Spondyloarthritis
Journal ArticleJ Rheumatol, 2024.
Recently finished projects
- Platelets and neutrophils: the two culprits mediating pain in inflammatory arthritis, from 2020-01-01 to 2022-12-31